The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects

• Published in: HIV medicine Vol. 16; no. 5; pp. 288 - 296
• Main Authors: Ruane, PJ, Brinson, C, Ramgopal, M, Ryan, R, Coate, B, Cho, M, Kakuda, TN, Anderson, D
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2015
• Subjects: Adult; Adverse events; Aged; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - pharmacokinetics; Antiretroviral agents; Antiretroviral therapy; Body fat; Body Fat Distribution; Bone Density - drug effects; Bone mineral density; CD4 Lymphocyte Count; Darunavir; Diarrhea; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; etravirine; Fat metabolism; Female; Glucose metabolism; HIV; HIV Infections - drug therapy; HIV-1 - drug effects; HIV‐1; Human immunodeficiency virus; Human immunodeficiency virus 1; Humans; Immune response; Immunology; Labels; Lipid metabolism; Lipids; Lipids - blood; Male; Middle Aged; Nucleosides; nucleoside‐sparing; Pharmacodynamics; Pharmacokinetics; Pyridazines - administration & dosage; Pyridazines - pharmacokinetics; race; Respiratory tract; Respiratory tract infection; Ritonavir; Ritonavir - administration & dosage; Ritonavir - pharmacokinetics; RNA, Viral - drug effects; RNA-directed DNA polymerase; Sulfonamides - administration & dosage; Sulfonamides - pharmacokinetics; Treatment Outcome; treatment‐experienced; Viral Load - drug effects; HIV-1; etravirine; darunavir; nucleoside-sparing; treatment-experienced; race

Objectives Following antiretroviral therapy failure, patients are often treated with a three‐drug regimen that includes two nucleoside/tide reverse transcriptase inhibitors [N(t)RTIs]. An alternative two‐drug nucleoside‐sparing regimen may decrease the pill burden and drug toxicities associated with...